MR
Therapeutic Areas
Vistagen Therapeutics Pipeline
| Drug | Indication | Phase |
|---|---|---|
| Fasedienol (PH94B) | Social Anxiety Disorder | Phase 3 |
| Itruvone (PH10) | Major Depressive Disorder | Phase 2 |
| PH80 | Prevention of Migraine | Preclinical |
Leadership Team at Vistagen Therapeutics
SK
Shawn K. Singh
Chief Executive Officer, Director
JS
Joshua S. Prince
Chief Business Officer
RG
Reid G. Adler
Chief Corporate Development Officer
C(
Cynthia (Cindi) V. Anderson
Chief Financial Officer
R(
Robert (Bobby) W. Azelby
Chairman of the Board